After 11 days of testimony, the federal record reveals something more consequential than a debate over schedules: a national gap between cannabis access and competent clinical care.
Editorial note: This article analyzes the completed evidentiary hearings in DEA Docket No. 1362, Hearing Docket No. 26-96. It is not a report of a final agency ruling, and it should not be read as an endorsement of every medical-cannabis claim presented during the proceedings. It is a nursing interpretation of the clinical, evidentiary, and policy issues exposed by the testimony.
For 11 hearing days, the federal government, physicians, scientists, pharmacists, law-enforcement officials, drug-testing professionals, policy advocates, and affected families presented testimony concerning the proposed transfer of marijuana from Schedule I to Schedule III of the Controlled Substances Act.
The official transcripts span more than 2,000 pages.
Beneath the legal arguments and adversarial exchanges, one truth appeared again and again: millions of patients already have access to cannabis, but access has developed faster than consistent clinical assessment, evidence-based education, outcome monitoring, and professional accountability.
That is not merely a regulatory problem. It is a nursing problem – and a nursing opportunity.
The hearings did not establish that cannabis is harmless, uniformly effective, equivalent to an FDA-approved medication, or appropriate for every patient. They also did not sustain the increasingly difficult claim that marijuana has no accepted medical use anywhere in the United States.
What emerged was a more complex and clinically honest picture: cannabis may offer meaningful benefit for some patients and indications, while presenting real and sometimes serious risks that vary according to the patient, product, potency, dose, route, frequency, comorbidities, concurrent medications, and context of use.
Nurses should understand that complexity before the final federal decision arrives.
First, what is the DEA considering?
The proposed rule would transfer marijuana, as defined under federal law and excluding products already separately scheduled, from Schedule I to Schedule III.
This is not the same as legalization.
Schedule III substances remain controlled. Federal requirements governing manufacture, distribution, dispensing, recordkeeping, and possession would continue to apply. Rescheduling would not automatically legalize state cannabis markets, transform dispensary products into FDA-approved drugs, or convert a clinician’s state-law cannabis recommendation into a federally valid prescription.
That distinction was one of the most important—and most frequently blurred—issues in the hearing record.
The scheduling inquiry is narrower. It considers whether marijuana has a currently accepted medical use in the United States, how its abuse potential compares with substances in other schedules, and whether its physical or psychological dependence liability is consistent with Schedule III.
The question is not whether cannabis can cause harm. Schedule III does not mean harmless. The more precise question is whether the total evidence continues to justify Schedule I – the category reserved for substances considered to have no currently accepted medical use and a high potential for abuse.
The central dispute was about how medical use is recognized
The hearing repeatedly returned to the meaning of “currently accepted medical use.”
The Department of Health and Human Services relied on an approach that considered two broad realities: marijuana is used medically on a widespread basis through state-authorized programs, and credible scientific support exists for at least some therapeutic uses.
Opponents argued for a more conventional pharmaceutical standard. They emphasized the absence of uniform chemistry, standardized dosing, reproducible products, adequate controlled trials for many indications, broad professional consensus, and the safety documentation ordinarily expected through the FDA drug-approval process.
Those concerns are legitimate. But they do not necessarily answer the same legal question.
A substance can lack FDA approval as a botanical product while still being used medically by patients and clinicians across most of the country. Conversely, widespread use does not prove that every claimed indication is effective or that every available product is safe.
Both statements can be true.
This distinction matters because much of the disagreement was not simply about what the studies showed. It was about which evidence should count when federal law evaluates medical acceptance outside the traditional new-drug pathway.
State programs are evidence – but not clinical trials
State medical-cannabis programs occupied two very different roles in the testimony.
For the government and its clinical witness, these programs demonstrated that medical use is neither isolated nor experimental. Patients receive cannabis for therapeutic purposes through established legal and regulatory systems. Clinicians evaluate or certify patients, state agencies oversee access, and regulated businesses provide labeled products.
For opposing witnesses, the same programs revealed inconsistent clinical standards: broad condition lists, variable certification practices, limited product-specific dosing, fragmented follow-up, diversion, and uncertainty about who is responsible when adverse effects occur.
Again, both descriptions can be accurate.
State programs demonstrate widespread acceptance and real-world medical use. They were not designed to determine efficacy through randomization, blinding, standardized products, or placebo control. Patient enrollment is not proof that a treatment works, just as the absence of an FDA-approved botanical product is not proof that no patient benefits.
The responsible conclusion lies between those extremes.
Real-world experience can identify therapeutic signals, patient priorities, adverse events, and questions that deserve formal study. Controlled research can estimate efficacy and risk more reliably, but it may fail to capture the product diversity, individualized dosing, and complex patients encountered in practice.
Cannabis nursing must be fluent in both forms of knowledge without confusing one for the other.
The hearing did not produce one verdict on efficacy
The testimony did not support a single statement that “cannabis works” or “cannabis does not work.”
Evidence differed substantially by indication, formulation, outcome, and patient population.
The record discussed stronger therapeutic support for selected pain outcomes, chemotherapy-related nausea and vomiting, and certain approved or standardized cannabinoid medicines. Evidence for psychiatric treatment, glaucoma, and many of the expansive conditions authorized by individual states was more contested or limited.
That distinction was especially visible during the testimony of physicians appearing on opposing sides.
The clinician supporting rescheduling described individualized cannabis care, including reviewing medications, considering alternatives, selecting routes and products, establishing therapeutic goals, and monitoring patient response. He also acknowledged important limitations: he would not recommend marijuana during pregnancy; a physiological effect alone does not establish sound treatment; evidence and professional guidance matter; and conventional therapies may be safer and more effective for conditions such as glaucoma.
Opposing psychiatric and pain specialists appropriately emphasized limited evidence for psychiatric indications, psychosis risk, cannabis-use disorder, variable dosing, high-potency products, and weaknesses in some state certification systems. Yet some also acknowledged legitimate therapeutic evidence for limited cannabinoid indications or distinguished approved isolated cannabinoids from botanical marijuana.
These concessions matter.
They reveal that the genuine dispute is not between “medicine” and “no medicine.” It concerns which products, which uses, which patients, under what conditions, and with what level of clinical oversight.
Safety cannot be reduced to a slogan
No credible reading of the transcripts supports describing cannabis as universally safe.
Witnesses raised clinically important concerns involving:
- Acute psychiatric reactions and psychosis, particularly with high-THC exposure or preexisting vulnerability
- Cannabis-use disorder, tolerance, and withdrawal
- Cognitive and psychomotor impairment
- Driving and workplace safety
- Cannabinoid hyperemesis syndrome
- Cardiovascular symptoms and possible cardiovascular events
- Pregnancy, lactation, adolescence, and neurodevelopment
- Drug-drug interactions and additive sedation
- Inaccurate labels, contaminants, and inconsistent potency
- Accidental pediatric exposure
Nurses should take every one of these concerns seriously.
At the same time, risk claims require the same critical appraisal as benefit claims. Several arguments moved too easily between medical use and recreational exposure, between lower-dose products and high-potency concentrates, or between botanical cannabis, isolated cannabinoids, intoxicating hemp derivatives, and synthetic cannabinoids.
These exposures are not clinically interchangeable.
Association studies and emergency-department cases can reveal meaningful safety signals. They do not always establish causation, quantify absolute risk, or tell us how cannabis compares with opioids, sedatives, antipsychotics, anticonvulsants, and other therapies a patient may use or replace.
An evidence-informed nurse asks not only, “Can this cause harm?” but also:
- How often does the harm occur?
- In whom is the risk greatest?
- What product, potency, dose, route, and frequency were involved?
- Was the use medically supervised or recreational?
- What other medications or substances were present?
- What was the risk of the untreated condition?
- What are the risks and benefits of the available alternatives?
That is not minimizing risk. It is practicing clinically.
Some of the most powerful testimony was not the strongest evidence
The hearing included deeply affecting testimony from bereaved family members and professionals who have witnessed impaired driving, psychosis, environmental damage, illicit cultivation, exploitation, and emergency medical crises.
These experiences belong in the public record. They identify preventable harms, failures of education, and consequences that statistical summaries can obscure.
They must also be interpreted according to what they can establish.
A personal tragedy may expose a sentinel event and an urgent need for prevention. It cannot, by itself, determine population incidence or comparative abuse potential. A sheriff can authoritatively describe illicit cultivation and enforcement burdens but cannot resolve therapeutic efficacy. A forensic laboratory specialist can explain testing and product identification but not whether a treatment produces meaningful clinical benefit. A psychiatrist’s testimony is strongest when applied to psychiatric risks and indications, not automatically to every area of medicine.
Expertise has boundaries.
One of the most important lessons for nurses is that testimony may be sincere, powerful, and relevant without being sufficient to answer every question placed before the tribunal.
The most consequential gap was clinical responsibility
Across witnesses with sharply different policy positions, the hearings exposed recurring weaknesses in patient care:
- Incomplete assessment before cannabis authorization
- Limited review of medical records and concurrent medications
- Inconsistent screening for psychiatric vulnerability or substance-use risk
- Inadequate product-specific dosing guidance
- Poor communication between recommending clinicians and the broader care team
- Uncertainty about who manages adverse effects
- Insufficient follow-up and outcome documentation
- Limited patient education about impairment, interactions, driving, pregnancy, and high-potency products
These are not arguments for abandoning patients who use cannabis. They are arguments for improving care.
Nurses are already positioned at the intersection of assessment, medication reconciliation, patient education, harm reduction, symptom monitoring, care coordination, and advocacy. Cannabis use should be integrated into those responsibilities rather than treated as an embarrassing disclosure, an automatic contraindication, or an issue belonging only to the dispensary.
The hearing record points toward a practical nursing standard.
When a patient uses cannabis, nurses should seek to understand:
- The reason for use and the patient’s desired outcome
- The actual product, cannabinoid profile, route, dose or amount, frequency, and timing
- The source of the product and available label or testing information
- Prior benefits, adverse effects, tolerance, withdrawal, or escalating use
- Concurrent medications, alcohol, nicotine, and other substances
- Psychiatric history, suicidality, cognitive vulnerability, and family history of psychosis
- Cardiovascular, fall, driving, occupational, pregnancy, lactation, and pediatric-exposure risks
- Other treatments attempted and whether cannabis is replacing or adding to therapy
- Responsibility for follow-up and the plan for urgent symptoms
- Whether the patient understands the difference between legal access, federal scheduling, FDA approval, and evidence of efficacy
This is the work of nursing assessment, clinical reasoning, education, and documentation.
What Schedule III would -and would not- mean for nursing
If marijuana is ultimately transferred to Schedule III, nurses and patients will need accurate education immediately.
Rescheduling would represent a significant federal recognition that marijuana has a currently accepted medical use and that its abuse and dependence profile does not warrant continued Schedule I placement.
It would not mean:
- Every cannabis product is FDA approved
- Every state-authorized indication is supported by strong evidence
- Dispensary products can automatically be prescribed like conventional Schedule III medications
- Cannabis is safe for every patient
- Impairment and workplace concerns disappear
- State and federal cannabis law become fully aligned
- Clinical monitoring is no longer necessary
In fact, recognition of medical use should increase clinical responsibility, not reduce it.
Greater legitimacy should bring better assessment, clearer documentation, more rigorous education, stronger adverse-event surveillance, improved research, and more accountable follow-up.
What the hearings reveal about the future of cannabis nursing
The federal record repeatedly addressed physicians, scientists, pharmacists, law enforcement, laboratories, regulators, advocates, and patients. Nursing expertise was not prominent.
That absence is significant.
Nurses are the professionals most consistently positioned to observe how therapies function in real lives: whether patients understand instructions, whether symptoms improve, whether adverse effects emerge, whether medications interact, whether a care plan is realistic, and whether stigma prevents honest communication.
Cannabis nursing can help close the gap between access and competent care by advancing:
- Standardized cannabis-use assessment
- Product- and indication-specific education
- Nonjudgmental medication reconciliation
- Mental-health and substance-use screening
- Therapeutic and adverse-outcome monitoring
- Interprofessional communication
- Patient-centered harm reduction
- Facility policies that protect both patients and staff
- Continuing clinical competency
- Research questions grounded in actual patient experience
The strongest response to the safety concerns raised during the hearings is not silence, stigma, or professional avoidance. It is better clinical practice.
The strongest response to exaggerated therapeutic claims is not denial of all medical value. It is evidence literacy.
And the strongest response to a fragmented system is not to leave patients to navigate it alone. It is to prepare nurses to care for them.
The decision is still ahead
The evidentiary hearings are complete, but the administrative process is not. The official transcripts, transcript corrections, exhibits, and post-hearing arguments must be evaluated before a final federal outcome is known.
Until then, nurses should resist both celebration and alarmism.
Whatever schedule ultimately appears in federal regulation, patients are already using cannabis. They are already combining it with prescriptions, undergoing procedures, entering hospitals, managing chronic illnesses, becoming pregnant, driving, working in safety-sensitive environments, and asking clinicians questions.
The clinical responsibility exists now.
The DEA hearings did not settle every scientific dispute. They did something equally important: they made visible the distance between the reality of cannabis use and the consistency of cannabis care.
That is the space in which nursing must lead.
About this analysis
Cannabis Nurses Network reviewed the complete set of 11 official DEA hearing transcripts for the proposed rescheduling of marijuana, encompassing more than 2,000 pages of testimony. The review distinguished sworn testimony from attorney argument, professional expertise from advocacy, clinical research from observational evidence, and personal experience from population-level proof.
Read the official DEA hearing record.
This article is educational and does not constitute legal or medical advice.
